Načítá se...
Cholinesterase inhibitors may not benefit mild cognitive impairment and mild Alzheimer disease dementia
INTRODUCTION: We investigated whether cholinesterase inhibitors (ChEIs) benefit cognitive outcomes in mild cognitive impairment (MCI) due to Alzheimer disease (AD) and in mild AD dementia. METHODS: Data from 2,242 individuals, clinically diagnosed with MCI due to AD (MCI-AD, Clinical Dementia Rating...
Uloženo v:
| Vydáno v: | Alzheimer Dis Assoc Disord |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6542289/ https://ncbi.nlm.nih.gov/pubmed/30633043 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/WAD.0000000000000291 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|